Reshoring pharma and med tech manufacturing: playing the long game

With the unexpected impact of COVID-19 on the supply chain for essential medicines and personal protective equipment, governments around the world are leaning towards re-shoring of strategic manufacturing capabilities for business continuity. This will have significant downstream implications across multiple areas.

Join our panel to understand the barriers and opportunities for securing your organization’s business continuity.

Discussion topics will include:

1. The latest information on the administration’s actions and guidance, including an understanding of what “made in America” means for life sciences business
2. Pricing challenges and sourcing strategies, including how to address capital and time needed to re-shore manufacturing
3. Significance of potential tax implications
4. An understanding of how to assess the quality of drug manufacturing vs. the cost
5. How to apply for BARDA and other government funding